In:
The Journal of Dermatology, Wiley, Vol. 45, No. 5 ( 2018-05), p. 600-602
Abstract:
Bullous pemphigoid ( BP ) is a common autoimmune blistering disorder with unknown etiology. Recently, increasing numbers of BP cases which developed under the medication with dipeptidyl peptidase‐4 inhibitors ( DPP 4i), widely used antihyperglycemic drugs, have been reported in published works. Here, we report a case of DPP 4i (teneligliptin)‐associated BP that developed in a 70‐year‐old Japanese man. Interestingly, the patient had acquired reactive perforating collagenosis ( ARPC ), which is also known to be associated with the onset of BP . In the present case, clinical, histopathological and immunological findings suggested that DPP 4i rather than ARPC was associated with the onset of BP .
Type of Medium:
Online Resource
ISSN:
0385-2407
,
1346-8138
DOI:
10.1111/jde.2018.45.issue-5
DOI:
10.1111/1346-8138.14254
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2222121-9
Bookmarklink